SCHEMBL9890814

SCHEMBL9890814

CC(=O)NC[C@H]1CN(c2ccc(OCC3(CP(=O)(OCc4ccccc4)OCc4ccccc4)CCN(c4cc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TOP2B Q02880 3/20 0.46
MAOA P21397 3/20 0.43
LMNA P02545 3/20 0.43
MAOB P27338 2/20 0.43
PTGS1 P23219 1/20 0.43
CALML3 P27482 1/20 0.43
SDHA P31040 1/20 0.43
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 3/20 0.42
HPGD P15428 2/20 0.42
HSD17B10 Q99714 2/20 0.42
MAPT P10636 1/20 0.42
PIK3CG P48736 2/20 0.41
PIK3CD O00329 1/20 0.41
PIK3R1 P27986 1/20 0.41
PIK3CA P42336 1/20 0.41
CYP1A2 P05177 1/20 0.40
TOP2A P11388 1/20 0.40
CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2108803 0.91 TOP2B (0.47) TOP2BMAOALMNAMAOBPTGS1
SCHEMBL12342302 0.88 TOP2B (0.47) TOP2BMAOALMNAMAOBPTGS1
SCHEMBL702285 0.86 TOP2B (0.52) TOP2BMAOALMNAMAOBPTGS1
SCHEMBL29433777 0.86 TOP2B (0.52) TOP2BMAOALMNAMAOBPTGS1
SCHEMBL9890815 0.86 TOP2B (0.49) TOP2BMAOALMNAMAOBPTGS1
SCHEMBL2109002 0.86 TOP2B (0.49) TOP2BMAOALMNAMAOBPTGS1
SCHEMBL29395141 0.86 TOP2B (0.49) TOP2BMAOALMNAMAOBPTGS1
SCHEMBL16274030 0.85 TOP2B (0.51) TOP2BMAOALMNAMAOBPTGS1
SCHEMBL28488322 0.85 TOP2B (0.51) TOP2BMAOALMNAMAOBPTGS1
SCHEMBL22642711 0.84 TOP2B (0.51) TOP2BMAOALMNAMAOBPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501774-B2 Oxazolidinone-quinolone hybrid antibiotics Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) 2013-08-06 US disclosed
US-8501774-B2 Oxazolidinone-quinolone hybrid antibiotics Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) 2013-08-06 US disclosed
US-20120142635-A1 OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) 2012-06-07 US disclosed
US-20120142635-A1 OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142635-A1 OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS OXA1L, TOP1, TOP2A TOP2B 13/4885MAOA 1595/4885LMNA 3615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.